Micro Cap Biotechnology
Stocks Ranked by
Market Capitalization
Micro Cap Biotechnology Stocks at a Glance
Biotechnology companies research and develop novel drugs and therapies, often with no products yet on the market. Clinical-trial readouts and regulatory decisions drive binary stock moves, making pipeline breadth, cash runway, and partnership deals the key variables.
There are 273 micro cap Biotechnology stocks — companies in the Biotechnology industry with a market cap under $250M — worth a combined $18.3B.
The largest by market cap are Greenwich LifeSciences (GLSI) at $248M, Adagene (ADAG) at $248M and Capricor Therapeutics (CAPR) at $243M.
Among institutional investors, Atrium Therapeutics (RNA) drew the most net new fund positions in Q1 2026: 162 funds opened new positions.
- Combined market cap: $18.3B across 273 stocks.
- Micro Cap: market cap under $250M.
- Largest constituent: Greenwich LifeSciences (GLSI), $248M market cap.
- Most net new fund positions in Q1 2026: Atrium Therapeutics (RNA), +162 holders.
Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q1 2026.